In:
Archives of Disease in Childhood - Fetal and Neonatal Edition, BMJ, Vol. 106, No. 2 ( 2021-03), p. 211-214
Abstract:
Less-invasive surfactant administration (LISA) is increasingly used. We investigated the feasibility of a new LISA-device (Neofact®) in neonates. Design Prospective observational pilot study with open-label LISA in two tertiary neonatal intensive care units. Patients 20 infants with a gestational age of ≥26+0/7 weeks and an indication for LISA (Respiratory Severity Score (RSS)≥5 or fraction of inspired oxygen (FiO 2 ) ≥0.30). Infants with respiratory tract malformations or unavailability of an instructed neonatologist were excluded. Main outcome measures Success of LISA, defined as laryngoscopy-confirmed intratracheal catheter position or a decrease in FiO 2 by ≥0.05 or to 0.21, accompanied by an RSS decrease of ≥2; number of attempts needed for tracheal catheterisation. Results 20/57 screened infants were enrolled. Successful application occurred in 19/20 (95%). One application failed after three attempts. No device-related adverse events occurred. The median number of attempts was 2, success rate per attempt 19/31 (61%). Conclusion LISA via Neofact® appears feasible.
Type of Medium:
Online Resource
ISSN:
1359-2998
,
1468-2052
DOI:
10.1136/archdischild-2020-319792
Language:
English
Publisher:
BMJ
Publication Date:
2021
detail.hit.zdb_id:
2188490-0
